Yüklüyor......
PI3Kδ-Selective and PI3Kα/δ-Combinatorial Inhibitors in Clinical Development for B-Cell Non-Hodgkin Lymphoma
INTRODUCTION: Phosphatidylinositol-3-kinase (PI3K) inhibitors comprise a novel class of agents that are effective for the treatment of chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (iNHL). The demonstrated efficacy and subsequent FDA approval of the prototypical PI3Kδ inhibito...
Kaydedildi:
| Yayımlandı: | Expert Opin Investig Drugs |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5747968/ https://ncbi.nlm.nih.gov/pubmed/28945111 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/13543784.2017.1384815 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|